Exploration of binding site pattern in arachidonic acid metabolizing enzymes, Cyclooxygenases and Lipoxygenases

• Published in: BMC research notes 2015-04, Vol.8 (1), p.152-152, Article 152
• Main Authors: Reddy, Kakularam Kumar, Vidya Rajan, Veena Kumari, Gupta, Ashish, Aparoy, Polamarasetty, Reddanna, Pallu
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Amino acids; Analysis; Arachidonate 12-Lipoxygenase - chemistry; Arachidonate 15-Lipoxygenase - chemistry; Arachidonate 5-Lipoxygenase - chemistry; Arachidonic acid; Arachidonic Acid - chemistry; Binding Sites; Chemical properties; Conserved Sequence; COX-2 inhibitors; Cyclooxygenase 1 - chemistry; Cyclooxygenase 2 - chemistry; Enzyme inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Inflammation; Lipoxygenase - chemistry; Molecular Docking Simulation; Molecular Sequence Data; Physiological aspects; Prostaglandins; Protein Binding; Protein Structure, Tertiary; Scavenger Receptors, Class E - chemistry; Sequence Alignment; Sequence Homology, Amino Acid; Unsaturated fatty acids
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/s13104-015-1101-4

Cyclooxygenase (COXs) and Lipoxygenase (LOXs) pathways are the two major enzymatic pathways in arachidonic acid (AA) metabolism. The term eicosanoid is used to describe biologically active lipid mediators including prostaglandins, thromboxanes, leukotrienes and other oxygenated derivatives, which are produced primarily from AA. Eicosanoids generated in a tissue specific manner play a key role in inflammation and cancer. As AA is the substrate common to variety of COXs and LOXs, inhibition of one pathway results in diversion of the substrate to other pathways, which often is responsible for undesirable side effects. Hence there is need for development of not only isozyme specific inhibitors but also dual/multi enzyme inhibitors. Understanding the interactions of AA and characterizing its binding sites in these enzymes therefore is crucial for developing enzyme specific and multi enzyme inhibitors for enhancing therapeutic efficacy and/or overcoming side effects. AA binding sites in COXs and LOXs are identified and compared by the development of receptor based pharmacophore using MultiBind. Physico chemical properties were compared to understand the details of the binding sites in all the enzymes and to elucidate important amino acids that can be targeted for drug design. The alignment of AA binding sites in the seven enzymes COX-1, COX-2, 5-LOX, 12-LOX, 15-LOX and plant soybean LOX-1 and LOX-3 indicated a common pattern of five common interacting groups. In the same way, comparison of AA binding sites was done pair wise and by multiple alignment in various combinations. It has been identified that aliphatic and aromatic interactions are the most common in all the enzymes. In addition interactions unique to each one of these enzymes were identified. The complete analysis of AA binding sites in the seven enzymes was performed; 120 combinations for the seven enzymes were studied in detail. All the seven enzymes are structurally quite different, yet they share AA as the common binding partner. Comparisons in various combinations showed how they are similar and dissimilar with each other. This information will be helpful in designing specific as well as common inhibitors.